



**FINANCIAL DATA  
(IFRS)  
3rd Quarter  
Fiscal Year Ending March 31, 2018  
[2018年3月期 第3四半期]  
April 1, 2017 – December 31, 2017**

| 目次                            | CONTENTS  |    |
|-------------------------------|---|----|
| <連結データ> < Consolidated Data > |   |    |
| 連結決算概要                        | Financial Summary(Consolidated)   | 1  |
| 連結財政状態計算書                     | Consolidated statement of financial position  | 3  |
| 連結損益計算書                       | Consolidated statement of income  | 5  |
| 連結キャッシュフロー計算書                 | Consolidated statement of cash flows  | 6  |
| 地域別・事業別・品目別売上高                | Net Sales by Destination, Business and Product type   | 8  |
| 地域別・事業別売上高                    | Net Sales by Destination and Business   | 9  |
| 地域別・品目別売上高                    | Net Sales by Destination and Product type   | 12 |
| 所在地別売上高および営業利益の状況             | Net Sales and Operating Income (Loss) by Geographical Region<br>(Net Sales and Operating Income (Loss) of Subsidiaries in the Region) | 13 |
| <関連データ> < Associated Data >   |   |    |
| 株式情報                          | Stock Information   | 14 |
| 会社概要                          | Corporate Data  | 15 |

- 2017年3月期よりIFRSを適用し、2017年3月期第1四半期からIFRSに基づき開示しています。
- From fiscal year ending March 31, 2017, Sysmex adopts IFRS and disclose financial information based on IFRS from the first three months of the fiscal year ending March 31, 2017.
- 2016年3月期第3四半期にシスメックス ウェストアンドセントラルアフリカをガーナに設立しました。
- In the 3rd quarter of e fiscal year ending March 31st, 2016, Sysmex established Sysmex West and Central Africa Ltd. in Ghana.
- 2014年4月1日付で1株を2株に株式分割を実施しました。
- The shares of shareholders was split two for one on April 1, 2014.
- 2014年3月期第3四半期にアイノスティクス ゲーエムベーハー及びその関係会社を子会社化しました。
- In the 3rd quarter of the fiscal year ending March 31, 2014, Inostics GmbH and its affiliated companies were converted to subsidiaries.
- 2014年3月期第2四半期にバルテック ゲーエムベーハー ゲルリッツ及びその関係会社の持分を取得し、子会社化しました。
- In the 2nd quarter of the fiscal year ending March 31, 2014, Sysmex acquired Partec GmbH Görnitz and its ownership in affiliated companies and converted these companies to subsidiaries.
- 2014年3月期第1四半期の連結決算より、シスメックスビジネスサポート株式会社、シスメックスコアの業績が反映されています。
- At the beginning of 1st quarter of fiscal year ending March 31, 2014, the consolidated figures include the results of Sysmex Business Support Co., Ltd. and Sysmex Korea Co., Ltd.
- 2011年4月1日付で1株を2株に株式分割を実施しました。
- The shares of shareholders was split two for one on April 1, 2011.

本資料のうち、業績見通し等に記載されている各数値は、現在入手可能な情報による判断および仮定に基づき算出しており、判断や仮定に内在する不確実性および今後の事業運営や内外の状況変化により、実際の業績等が見通しの数値と大きく異なる可能性があります。

#### Forward-looking Statements

This material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysmex Group). These forward-looking statements are based on current judgments and assumptions of the Sysmex Group in light of the information currently available to it, and involve known and unknown risks, uncertainties and other factors, including but not limited to: global economic conditions, competitive situations and changes in exchange rates. Such risks, uncertainties and other factors may cause our actual results, performance, achievements or

Financial Summary (Consolidated) [3rd Quarter]

(百万円) (構成比:%)  
(¥ million) (Ratio: %)

| 項目 Item               | 決算期 Fiscal Term  | 2016.3 3Q | 2017.3 3Q | 2018.3 3Q | 2018.3 通期予想<br>Forecast |
|-----------------------|--|-----------|-----------|-----------|-------------------------|
| 売上高                   | Net sales  | 185,685   | 180,793   | 202,551   | 280,000                 |
| 売上原価                  | Cost of sales  | 74,097    | 76,241    | 87,373    | 121,300                 |
| 売上総利益                 | Gross profit   | 111,587   | 104,552   | 115,178   | 158,700                 |
| 販売費及び一般管理費            | Selling, general and administrative expenses             | 55,261    | 54,859    | 59,024    | 83,200                  |
| 研究開発費                 | Research and development expenses                        | 10,603    | 11,391    | 11,921    | 17,500                  |
| その他の営業損益              | Other operating income (expenses)                        | 308       | 858       | 350       | -                       |
| 営業利益                  | Operating profit   | 46,032    | 39,160    | 44,583    | 58,000                  |
| 四半期(当期)利益             | Profit   | 29,704    | 31,840    | 30,359    | 41,500                  |
| 親会社の所有者に帰属する四半期(当期)利益 | Profit attributable to owners of the parent              | 29,704    | 31,967    | 30,555    | 41,500                  |
| 希薄化後1株当たり四半期(当期)利益(円) | Diluted earnings per share(¥)                            | 142.41    | 153.19    | 146.37    | 198.82                  |
| 親会社所有者帰属持分四半期(当期)利益率  | Return on equity[ROE]                                    | -         | -         | -         | -                       |
| 売上総利益率                | Gross profit per net sales                               | 60.1      | 57.8      | 56.9      | 56.7                    |
| 売上高営業利益率              | Operating profit to net sales                            | 24.8      | 21.7      | 22.0      | 20.7                    |
| 売上高四半期(当期)利益率         | Profit attributable to owners of the parent to net sales | 16.0      | 17.6      | 15.1      | 14.8                    |
| 売上高研究開発費率             | R&D expenditure per net sales                            | 5.7       | 6.3       | 5.9       | 6.3                     |

| 項目 Item            | 決算期 Fiscal Term  | 2016.3 F.Y. | 2017.3 F.Y. | 2018.3 3Q |
|--------------------|--|-------------|-------------|-----------|
| 資本金                | Capital stock  | 11,016      | 11,611      | 12,013    |
| 自己株式控除後期末株式数(千株)   | Number of outstanding stock excluding treasury stock (thousand shares) | 207,888.3   | 208,186.4   | 208,387.4 |
| 資本合計               | Total equity   | 182,801     | 210,252     | 236,990   |
| 資産合計               | Total assets   | 263,917     | 279,817     | 310,612   |
| 親会社所有者帰属持分比率       | Equity attributable to owners of the parent to total assets            | 69.3        | 74.8        | 76.1      |
| 1株当たり親会社所有者帰属持分(円) | Equity attributable to owners of the parent per share(¥)               | 879.32      | 1,005.86    | 1,134.17  |

| 項目 Item          | 決算期 Fiscal Term                                      | 2016.3 3Q | 2017.3 3Q | 2018.3 3Q |
|------------------|--|-----------|-----------|-----------|
| 営業活動によるキャッシュ・フロー | Net cash provided by (used in) operating activities  | 25,671    | 17,900    | 34,226    |
| 投資活動によるキャッシュ・フロー | Net cash provided by (used in) investment activities | △ 16,946  | △ 13,951  | △ 26,876  |
| 財務活動によるキャッシュ・フロー | Net cash provided by (used in) financing activities  | △ 8,908   | △ 11,063  | △ 12,021  |
| 現金及び現金同等物の期末残高   | Cash and cash equivalents at the end of the term     | 48,592    | 48,906    | 55,013    |

設備投資の状況  
Capital Expenditure

| 項目 Item    | 2016.3 3Q                     | 2017.3 3Q | 2018.3 3Q | 2018.3 通期予想<br>Forecast |        |
|------------|-------------------------------|-----------|-----------|-------------------------|--------|
| 設備投資       | Capital expenditure           | 9,243     | 7,500     | 7,441                   | 18,000 |
| 減価償却費及び償却費 | Depreciation and amortization | 8,953     | 9,026     | 10,892                  | 14,000 |

●通期予想は、2017年11月に修正したものです。  
●Business forecast was revised in November 2017.

### 換算レート（通期実績）

Average Exchange Rate (Annual)

|       |     | 決算期 Fiscal Term |     | 2014.3 F.Y. | 2015.3 F.Y. | 2016.3 F.Y. | 2017.3 F.Y. | 2018.3 通期予想<br>(Forecast) |
|-------|-----|-----------------|-----|-------------|-------------|-------------|-------------|---------------------------|
| USDドル | USD | (円)             | (¥) | 100.2       | 109.9       | 120.1       | 108.4       | 110.5                     |
| ユーロ   | EUR | (円)             | (¥) | 134.4       | 138.8       | 132.6       | 118.8       | 128.1                     |
| 元     | CNY | (円)             | (¥) | 16.3        | 17.8        | 18.9        | 16.1        | 16.5                      |

### 換算レート（期中平均）

Average Exchange Rates (Periods)

|         |     | 決算期 Fiscal Term |     | 2014.3 3Q | 2015.3 3Q | 2016.3 3Q | 2017.3 3Q | 2018.3 3Q |
|---------|-----|-----------------|-----|-----------|-----------|-----------|-----------|-----------|
| 項目 Item |     |                 |     |           |           |           |           |           |
| USDドル   | USD | (円)             | (¥) | 99.4      | 106.9     | 121.7     | 106.6     | 111.7     |
| ユーロ     | EUR | (円)             | (¥) | 132.2     | 140.3     | 134.4     | 118.0     | 128.5     |
| 元       | CNY | (円)             | (¥) | 16.1      | 17.4      | 19.3      | 16.0      | 16.6      |

●通期予想は、2017年11月に修正したものです。

●Forecast was revised in November 2017.

# 連結財政状態計算書

## Consolidated statement of financial position

### 資産 Assets

(百万円) (構成比:%)  
(¥ million) (Ratio:%)

| 項目 Item         | 2015.3 F.Y.※              |              | 2016.3 F.Y.    |              | 2017.3 F.Y.    |              | 2018.3 3Q      |              | 増減<br>(Variance) |
|-----------------|---------------------------|--------------|----------------|--------------|----------------|--------------|----------------|--------------|------------------|
|                 |                           | %            |                | %            |                | %            |                | %            |                  |
| <b>流動資産</b>     | <b>Current assets</b>     |              |                |              |                |              |                |              |                  |
| 現金及び現金同等物       | 49,613                    | 20.9         | 56,481         | 21.4         | 57,944         | 20.7         | 55,013         | 17.7         | △2,931           |
| 営業債権及びその他の債権    | 53,662                    | 22.6         | 57,652         | 21.8         | 63,084         | 22.5         | 66,760         | 21.5         | 3,676            |
| 棚卸資産            | 29,966                    | 12.6         | 35,604         | 13.5         | 36,998         | 13.2         | 46,306         | 14.9         | 9,308            |
| その他の短期金融資産      | 298                       | 0.1          | 615            | 0.2          | 528            | 0.2          | 309            | 0.1          | △219             |
| 未収法人所得税         | 223                       | 0.1          | 453            | 0.2          | 457            | 0.2          | 744            | 0.2          | 287              |
| その他の流動資産        | 6,484                     | 2.7          | 7,450          | 2.8          | 7,303          | 2.6          | 8,434          | 2.7          | 1,131            |
| <b>流動資産合計</b>   | <b>140,248</b>            | <b>59.1</b>  | <b>158,258</b> | <b>60.0</b>  | <b>166,318</b> | <b>59.4</b>  | <b>177,568</b> | <b>57.2</b>  | <b>11,250</b>    |
| <b>非流動資産</b>    | <b>Non-current assets</b> |              |                |              |                |              |                |              |                  |
| 有形固定資産          | 56,835                    | 23.9         | 59,282         | 22.5         | 60,144         | 21.5         | 63,029         | 20.3         | 2,885            |
| のれん             | 7,192                     | 3.0          | 6,921          | 2.6          | 8,308          | 3.0          | 12,975         | 4.2          | 4,667            |
| 無形資産            | 11,598                    | 4.9          | 16,682         | 6.3          | 21,228         | 7.6          | 29,237         | 9.4          | 8,009            |
| 持分法で会計処理されている投資 | 1,937                     | 0.8          | 2,089          | 0.8          | 552            | 0.2          | 1,026          | 0.3          | 474              |
| 営業債権及びその他の債権    | 3,901                     | 1.6          | 6,476          | 2.5          | 8,813          | 3.1          | 10,428         | 3.4          | 1,615            |
| その他の長期金融資産      | 6,440                     | 2.7          | 6,010          | 2.3          | 6,107          | 2.2          | 7,736          | 2.5          | 1,629            |
| 退職給付に係る資産       | 960                       | 0.4          | 582            | 0.2          | 666            | 0.2          | 644            | 0.2          | △22              |
| その他の非流動資産       | 1,717                     | 0.7          | 1,928          | 0.7          | 2,095          | 0.7          | 2,227          | 0.7          | 132              |
| 繰延税金資産          | 6,478                     | 2.7          | 5,684          | 2.2          | 5,581          | 2.0          | 5,737          | 1.8          | 156              |
| <b>非流動資産合計</b>  | <b>97,062</b>             | <b>40.9</b>  | <b>105,659</b> | <b>40.0</b>  | <b>113,499</b> | <b>40.6</b>  | <b>133,044</b> | <b>42.8</b>  | <b>19,545</b>    |
| <b>資産合計</b>     | <b>237,310</b>            | <b>100.0</b> | <b>263,917</b> | <b>100.0</b> | <b>279,817</b> | <b>100.0</b> | <b>310,612</b> | <b>100.0</b> | <b>30,795</b>    |

※2015年3月期末の数値は、IFRS移行日(2015年4月1日)の数値です。

※Figures indicated for March 31, 2015, are as of the IFRS transition date (April 1, 2015).

## 負債および資本

### Liabilities and Equity

(百万円) (構成比: %)  
(¥ million) (Ratio: %)

| 項目 Item          | 決算期 Fiscal Term | 2015.3 F.Y. ※                                      |              | 2016.3 F.Y.    |              | 2017.3 F.Y.    |              | 2018.3 3Q      |              | 増減<br>(Variance) |
|------------------|-----------------|--|--------------|----------------|--------------|----------------|--------------|----------------|--------------|------------------|
|                  |                 |  | %            |                | %            |                | %            |                | %            |                  |
| <b>負債</b>        |                 | <b>Liabilities</b>                                 |              |                |              |                |              |                |              |                  |
| <b>流動負債</b>      |                 | <b>Current liabilities</b>                         |              |                |              |                |              |                |              |                  |
| 営業債務及びその他の債務     |                 | 22,776   | 9.6          | 26,824         | 10.2         | 24,376         | 8.7          | 25,780         | 8.3          | 1,404            |
| その他の短期金融負債       |                 | 1,001  | 0.4          | 788            | 0.3          | 956            | 0.3          | 878            | 0.3          | △78              |
| 未払法人所得税          |                 | 9,418  | 4.0          | 6,511          | 2.5          | 2,915          | 1.0          | 7,373          | 2.4          | 4,458            |
| 引当金              |                 | 450  | 0.2          | 554            | 0.2          | 610            | 0.2          | 674            | 0.2          | 64               |
| 前受金              |                 | 10,357   | 4.4          | 10,431         | 4.0          | 6,418          | 2.3          | 4,454          | 1.4          | △1,964           |
| 未払費用             |                 | 8,137  | 3.4          | 6,864          | 2.6          | 8,330          | 3.0          | 10,244         | 3.3          | 1,914            |
| 未払賞与             |                 | 6,130  | 2.6          | 6,538          | 2.5          | 6,636          | 2.4          | 4,850          | 1.6          | △1,786           |
| その他の流動負債         |                 | 9,084  | 3.8          | 9,383          | 3.6          | 9,708          | 3.5          | 10,493         | 3.4          | 785              |
| <b>流動負債合計</b>    |                 | <b>67,355</b>                                      | <b>28.4</b>  | <b>67,896</b>  | <b>25.7</b>  | <b>59,952</b>  | <b>21.4</b>  | <b>64,749</b>  | <b>20.8</b>  | <b>4,797</b>     |
| <b>非流動負債</b>     |                 | <b>Non-current liabilities</b>                     |              |                |              |                |              |                |              |                  |
| 長期金融負債           |                 | 342  | 0.1          | 734            | 0.3          | 549            | 0.2          | 745            | 0.2          | 196              |
| 退職給付に係る負債        |                 | 562  | 0.2          | 566            | 0.2          | 654            | 0.2          | 748            | 0.2          | 94               |
| 引当金              |                 | 2,312  | 1.0          | 2,341          | 0.9          | 2,318          | 0.8          | 248            | 0.1          | △2,070           |
| その他の非流動負債        |                 | 3,094  | 1.3          | 3,192          | 1.2          | 3,527          | 1.3          | 2,765          | 0.9          | △762             |
| 繰延税金負債           |                 | 5,669  | 2.4          | 6,384          | 2.4          | 2,562          | 0.9          | 4,364          | 1.4          | 1,802            |
| <b>非流動負債合計</b>   |                 | <b>11,980</b>                                      | <b>5.0</b>   | <b>13,219</b>  | <b>5.0</b>   | <b>9,612</b>   | <b>3.4</b>   | <b>8,873</b>   | <b>2.9</b>   | <b>△739</b>      |
| <b>負債合計</b>      |                 | <b>79,336</b>                                      | <b>33.4</b>  | <b>81,116</b>  | <b>30.7</b>  | <b>69,564</b>  | <b>24.9</b>  | <b>73,622</b>  | <b>23.7</b>  | <b>4,058</b>     |
| <b>資本</b>        |                 | <b>Equity</b>                                      |              |                |              |                |              |                |              |                  |
| 親会社の所有者に帰属する持分   |                 | <b>Equity attributable to owners of the parent</b> |              |                |              |                |              |                |              |                  |
| 資本金              |                 | 10,483   | 4.4          | 11,016         | 4.2          | 11,611         | 4.1          | 12,013         | 3.9          | 402              |
| 資本剰余金            |                 | 16,340   | 6.9          | 16,969         | 6.4          | 17,303         | 6.2          | 17,517         | 5.6          | 214              |
| 利益剰余金            |                 | 130,183  | 54.9         | 159,375        | 60.4         | 188,506        | 67.4         | 206,568        | 66.5         | 18,062           |
| 自己株式             |                 | △280   | △0.1         | △285           | △0.1         | △289           | △0.1         | △295           | △0.1         | △6               |
| その他の資本の構成要素      |                 | 1,246  | 0.5          | △4,275         | △1.6         | △7,725         | △2.8         | 542            | 0.2          | 8,267            |
| 親会社の所有者に帰属する持分合計 |                 | 157,972  | 66.6         | 182,800        | 69.3         | 209,406        | 74.8         | 236,346        | 76.1         | 26,940           |
| 非支配持分            |                 | 0  | 0.0          | 0              | 0.0          | 845            | 0.3          | 643            | 0.2          | △202             |
| <b>資本合計</b>      |                 | <b>157,973</b>                                     | <b>66.6</b>  | <b>182,801</b> | <b>69.3</b>  | <b>210,252</b> | <b>75.1</b>  | <b>236,990</b> | <b>76.3</b>  | <b>26,738</b>    |
| <b>負債及び資本合計</b>  |                 | <b>237,310</b>                                     | <b>100.0</b> | <b>263,917</b> | <b>100.0</b> | <b>279,817</b> | <b>100.0</b> | <b>310,612</b> | <b>100.0</b> | <b>30,795</b>    |

※2015年3月期末の数値は、IFRS移行日(2015年4月1日)の数値です。

※Figures indicated for March 31, 2015, are as of the IFRS transition date (April 1, 2015).

(百万円) (構成比: %)  
(¥ million) (Ratio: %)

| 項目 Item            | 決算期 Fiscal Term  | 2016.3 3Q |       | 2017.3 3Q |       | 2018.3 3Q |       |
|--------------------|--|-----------|-------|-----------|-------|-----------|-------|
|                    |  |           | %     |           | %     |           | %     |
| 売上高                | Net sales  | 185,685   | 100.0 | 180,793   | 100.0 | 202,551   | 100.0 |
| 売上原価               | Cost of sales  | 74,097    | 39.9  | 76,241    | 42.2  | 87,373    | 43.1  |
| 売上総利益              | Gross profit   | 111,587   | 60.1  | 104,552   | 57.8  | 115,178   | 56.9  |
| 販売費及び一般管理費         | Selling, general and administrative expenses                               | 55,261    | 29.8  | 54,859    | 30.3  | 59,024    | 29.1  |
| 研究開発費              | Research and development expenses  | 10,603    | 5.7   | 11,391    | 6.3   | 11,921    | 5.9   |
| その他の営業収益           | Other operating income   | 494       | 0.3   | 1,109     | 0.6   | 471       | 0.2   |
| その他の営業費用           | Other operating expenses   | 185       | 0.1   | 250       | 0.1   | 120       | 0.1   |
| 営業利益               | Operating profit   | 46,032    | 24.8  | 39,160    | 21.7  | 44,583    | 22.0  |
| 金融収益               | Financial income   | 286       | 0.2   | 436       | 0.2   | 228       | 0.1   |
| 金融費用               | Financial expenses   | 49        | 0.0   | 99        | 0.1   | 139       | 0.1   |
| 持分法による投資損益         | Share of profit (loss) of associates accounted for using the equity method | △264      | △0.1  | △402      | △0.2  | △447      | △0.2  |
| 関連会社株式売却益          | Gain on Sales of Shares in Associates                                      | -         | -     | -         | -     | 1,221     | 0.6   |
| 為替差損益              | Foreign exchange gain (loss)   | △1,401    | △0.8  | △1,900    | △1.1  | △315      | △0.2  |
| 税引前四半期(当期)利益       | Profit before tax  | 44,603    | 24.0  | 37,194    | 20.6  | 45,130    | 22.3  |
| 法人所得税費用            | Income taxes expenses  | 14,899    | 8.0   | 5,353     | 3.0   | 14,770    | 7.3   |
| 四半期(当期)利益          | Profit   | 29,704    | 16.0  | 31,840    | 17.6  | 30,359    | 15.0  |
| 四半期(当期)利益の帰属       | Profit attributable to   |           |       |           |       |           |       |
| 親会社の所有者            | Owners of the parent   | 29,704    | 16.0  | 31,967    | 17.7  | 30,555    | 15.1  |
| 非支配持分              | Non-controlling interests  | △0        | △0.0  | △126      | △0.1  | △195      | △0.1  |
| 四半期(当期)利益          | Profit   | 29,704    | 16.0  | 31,840    | 17.6  | 30,359    | 15.0  |
| 1株当たり四半期(当期)利益     | Earnings per share   |           |       |           |       |           |       |
| 基本的1株当たり四半期(当期)利益  | Basic  | 143.02    | -     | 153.66    | -     | 146.72    | -     |
| 希薄化後1株当たり四半期(当期)利益 | Diluted  | 142.41    | -     | 153.19    | -     | 146.37    | -     |

Consolidated statement of cash flows [3rd Quarter]

(百万円)  
(¥ million)

| 項目 Item                 |  | 2016.3 3Q     | 2017.3 3Q     | 2018.3 3Q     |
|-------------------------|--|---------------|---------------|---------------|
| <b>営業活動によるキャッシュ・フロー</b> | <b>Cash flows from operating activities</b>                    |               |               |               |
| 税引前四半期(当期)利益            | Profit before tax  | 44,603        | 37,194        | 45,130        |
| 減価償却費及び償却費              | Depreciation and amortization                                  | 8,953         | 9,026         | 10,892        |
| 関連会社株式売却益               | Gain on Sales of Shares in Associates                          | -             | -             | △1,221        |
| 営業債権の増減額                | Decrease (increase) in trade receivable                        | 1,182         | △1,706        | 167           |
| 棚卸資産の増減額                | Decrease (increase) in inventories                             | △8,420        | △4,423        | △5,991        |
| 営業債務の増減額                | Increase (decrease) in trade payable                           | 4,740         | △2,221        | 2,818         |
| 未払又は未収消費税等の増減額          | Increase(Decrease) in consumption taxes receivable and payable | △212          | 1,598         | 745           |
| 前受金の増減額                 | Increase (decrease) in advances received                       | △4,600        | △4,765        | △2,303        |
| 未払賞与の増減額                | Increase (decrease) in accrued bonuses                         | △1,781        | △2,250        | △1,970        |
| その他                     | Other  | △451          | △23           | △4,192        |
| <b>小計</b>               | <b>Subtotal</b>  | <b>44,015</b> | <b>32,429</b> | <b>44,076</b> |
| 利息及び配当金の受取額             | Interest and dividend received                                 | 282           | 347           | 181           |
| 利息の支払額                  | Interest paid  | △9            | △60           | △59           |
| 法人所得税の支払額               | Income taxes paid  | △18,617       | △14,816       | △9,973        |
| <b>営業活動によるキャッシュ・フロー</b> | <b>Net cash provided by (used in) operating activities</b>     | <b>25,671</b> | <b>17,900</b> | <b>34,226</b> |



|                         |   | (百万円)<br>(¥ million) |                |                |
|-------------------------|---|----------------------|----------------|----------------|
| 項目 Item                 | 決算期 Fiscal Term   | 2016.3 3Q            | 2017.3 3Q      | 2018.3 3Q      |
| <b>投資活動によるキャッシュ・フロー</b> | <b>Cash flows from investing activities</b>                   |                      |                |                |
| 有形固定資産の取得による支出          | Purchases of property, plant and equipment                    | △10,364              | △8,199         | △8,587         |
| 無形資産の取得による支出            | Purchases of intangible assets                                | △5,758               | △5,474         | △6,953         |
| 資本性金融商品の取得による支出         | Purchases of investments in equity instruments                | △633                 | △629           | △1,815         |
| 資本性金融商品の売却による収入         | Proceeds from Sales of investments in equity instruments      | -                    | -              | 1,500          |
| 子会社又はその他の事業の取得による支出     | Acquisitions of subsidiaries or other businesses              | -                    | △1,453         | △10,980        |
| 短期貸付金の純増減額              | Net Decrease (Increase) in Short-term Loans Receivable        | -                    | 1,930          | -              |
| その他                     | Other   | △190                 | △125           | △39            |
| <b>投資活動によるキャッシュ・フロー</b> | <b>Net cash provided by (used in) investing activities</b>    | <b>△16,946</b>       | <b>△13,951</b> | <b>△26,876</b> |
| <b>財務活動によるキャッシュ・フロー</b> | <b>Cash flows from financing activities</b>                   |                      |                |                |
| 配当金の支払額                 | Dividends paid  | △9,549               | △11,646        | △12,493        |
| その他                     | Other   | 640                  | 583            | 472            |
| <b>財務活動によるキャッシュ・フロー</b> | <b>Net cash provided by (used in) financing activities</b>    | <b>△8,908</b>        | <b>△11,063</b> | <b>△12,021</b> |
| 現金及び現金同等物に係る換算差額        | Effects of exchange rate changes on cash and cash equivalents | △837                 | △460           | 1,740          |
| 現金及び現金同等物の純増減額          | Net increase (decrease) in cash and cash equivalents          | △1,021               | △7,575         | △2,931         |
| 現金及び現金同等物の期首残高          | Cash and cash equivalents at the beginning of the term        | 49,613               | 56,481         | 57,944         |
| 現金及び現金同等物の四半期末残高        | Cash and cash equivalents at the end of the term              | 48,592               | 48,906         | 55,013         |

## Net Sales by Destination, Business and Product type [3rd Quarter]

## 地域別売上高

## Net Sales by Destination

(百万円)  
(¥ million)

| 地域 Destination          | 決算期 Fiscal Term | 日本基準 J-GAAP |         |       |           |         |       | IFRS      |         |       |           |         |       | 2018.3 通期予想<br>(Forecast) |           |         |         |
|-------------------------|-----------------|-------------|---------|-------|-----------|---------|-------|-----------|---------|-------|-----------|---------|-------|---------------------------|-----------|---------|---------|
|                         |                 | 2014.3 3Q   |         |       | 2015.3 3Q |         |       | 2016.3 3Q |         |       | 2017.3 3Q |         |       |                           | 2018.3 3Q |         |         |
|                         |                 | Ratio (%)   | YOY (%) |       | Ratio (%) | YOY (%) |       | Ratio (%) | YOY (%) |       | Ratio (%) | YOY (%) |       |                           | Ratio (%) | YOY (%) |         |
| 国内 Japan                |                 | 27,896      | 21.5    | 101.7 | 28,389    | 18.2    | 101.8 | 28,444    | 15.3    | 100.2 | 30,870    | 17.1    | 108.5 | 32,251                    | 15.9      | 104.5   | 44,500  |
| 米州 Americas             |                 | 28,166      | 21.7    | 133.8 | 33,933    | 21.8    | 120.5 | 43,576    | 23.5    | 128.4 | 42,803    | 23.7    | 98.2  | 46,612                    | 23.0      | 108.9   | 66,000  |
| EMEA EMEA               |                 | 37,862      | 29.2    | 136.5 | 47,194    | 30.3    | 124.6 | 51,573    | 27.8    | 109.3 | 46,863    | 25.9    | 90.9  | 53,360                    | 26.3      | 113.9   | 73,700  |
| 中国 China                |                 | 26,063      | 20.1    | 144.9 | 34,636    | 22.2    | 132.9 | 48,517    | 26.1    | 140.1 | 45,444    | 25.1    | 93.7  | 52,321                    | 25.8      | 115.1   | 70,700  |
| アジア・パシフィック Asia-Pacific |                 | 9,859       | 7.6     | 137.8 | 11,698    | 7.5     | 118.7 | 13,573    | 7.3     | 116.0 | 14,811    | 8.2     | 109.1 | 18,005                    | 9.0       | 121.6   | 25,100  |
| 海外計 Overseas Total      |                 | 101,953     | 78.5    | 137.9 | 127,463   | 81.8    | 125.0 | 157,241   | 84.7    | 123.4 | 149,923   | 82.9    | 95.3  | 170,300                   | 84.1      | 113.6   | 235,500 |
| 合計 Total Sales          |                 | 129,849     | 100.0   | 128.1 | 155,852   | 100.0   | 120.0 | 185,685   | 100.0   | 119.1 | 180,793   | 100.0   | 97.4  | 202,551                   | 100.0     | 112.0   | 280,000 |

● EMEA: 欧州、中東、アフリカ地域 ● EMEA: Europe, the Middle East and Africa

## 事業別売上高

## Net Sales by Business

(百万円)  
(¥ million)

| 事業 Business                  | 決算期 Fiscal Term | 日本基準 J-GAAP |         |       |           |         |       | IFRS      |         |       |           |         |       | 2018.3 通期予想<br>(Forecast) |           |         |         |
|------------------------------|-----------------|-------------|---------|-------|-----------|---------|-------|-----------|---------|-------|-----------|---------|-------|---------------------------|-----------|---------|---------|
|                              |                 | 2014.3 3Q   |         |       | 2015.3 3Q |         |       | 2016.3 3Q |         |       | 2017.3 3Q |         |       |                           | 2018.3 3Q |         |         |
|                              |                 | Ratio (%)   | YOY (%) |       | Ratio (%) | YOY (%) |       | Ratio (%) | YOY (%) |       | Ratio (%) | YOY (%) |       |                           | Ratio (%) | YOY (%) |         |
| 血球計数検査 Hematology            |                 | 85,046      | 65.5    | 128.9 | 100,536   | 64.5    | 118.2 | 119,534   | 64.4    | 118.9 | 114,301   | 63.2    | 95.6  | 126,589                   | 62.5      | 110.8   | 176,100 |
| 尿検査 Urinalysis               |                 | 10,358      | 8.0     | 129.9 | 11,821    | 7.6     | 114.1 | 13,623    | 7.3     | 115.2 | 11,747    | 6.5     | 86.2  | 15,173                    | 7.5       | 129.2   | 21,100  |
| HU事業 HU Business             |                 | 95,405      | 73.5    | 129.0 | 112,358   | 72.1    | 117.8 | 133,157   | 71.7    | 118.5 | 126,048   | 69.7    | 94.7  | 141,763                   | 70.0      | 112.5   | 197,200 |
| 免疫検査 Immunochemistry         |                 | 1,581       | 1.2     | 111.0 | 2,297     | 1.5     | 145.2 | 4,094     | 2.2     | 178.2 | 5,868     | 3.2     | 143.3 | 7,909                     | 3.9       | 134.8   | 11,200  |
| 生化学検査 Clinical Chemistry     |                 | 2,506       | 1.9     | 128.7 | 2,773     | 1.8     | 110.7 | 2,699     | 1.5     | 97.3  | 2,546     | 1.4     | 94.3  | 2,576                     | 1.3       | 101.2   | 3,000   |
| 血液凝固検査 Hemostasis            |                 | 19,568      | 15.1    | 133.7 | 23,263    | 14.9    | 118.9 | 31,341    | 16.9    | 134.7 | 31,222    | 17.3    | 99.6  | 31,630                    | 15.6      | 101.3   | 43,800  |
| ICH事業 ICH Business           |                 | 23,656      | 18.2    | 131.4 | 28,335    | 18.2    | 119.8 | 38,135    | 20.5    | 134.6 | 39,637    | 21.9    | 103.9 | 42,116                    | 20.8      | 106.3   | 58,000  |
| コア事業 Core-Business           |                 | 119,061     | 91.7    | 129.5 | 140,693   | 90.3    | 118.2 | 171,293   | 92.2    | 121.7 | 165,686   | 91.6    | 96.7  | 183,879                   | 90.8      | 111.0   | 255,200 |
| FCM事業 FCM Business           |                 | -           | -       | -     | 1,905     | 1.2     | -     | 1,796     | 1.0     | 94.3  | 1,270     | 0.7     | 70.7  | 1,155                     | 0.6       | 90.9    | 2,700   |
| LS事業 Life Science Business   |                 | 1,078       | 0.8     | 148.8 | 2,108     | 1.4     | 195.5 | 2,555     | 1.4     | 121.2 | 3,159     | 1.7     | 123.6 | 6,016                     | 3.0       | 190.4   | 7,800   |
| その他 Other Next-Core Business |                 | -           | -       | -     | -         | -       | -     | -         | -       | -     | -         | -       | 0     | 0.0                       | -         | -       | 500     |
| ネクストコア事業 Next-Core Business  |                 | 1,078       | 0.8     | 148.8 | 4,013     | 2.6     | 372.1 | 4,352     | 2.3     | 108.4 | 4,429     | 2.4     | 101.8 | 7,171                     | 3.5       | 161.9   | 11,000  |
| その他 ※ Other Business ※       |                 | 9,708       | 7.5     | 111.4 | 11,145    | 7.2     | 114.8 | 10,039    | 5.4     | 90.1  | 10,678    | 5.9     | 106.4 | 11,499                    | 5.7       | 107.7   | 13,800  |
| 合計 Total Sales               |                 | 129,849     | 100.0   | 128.1 | 155,852   | 100.0   | 120.0 | 185,685   | 100.0   | 119.1 | 180,793   | 100.0   | 97.4  | 202,551                   | 100.0     | 112.0   | 280,000 |

※ 臨床検査情報システム、仕入れ商品等

※ Clinical laboratory information systems, sales of third-party products, others

## 品目別売上高

## Net Sales by Product Type

(百万円)  
(¥ million)

| 品目 Product Type                    | 決算期 Fiscal Term | 日本基準 J-GAAP |         |       |           |         |       | IFRS      |         |       |           |         |       | 2018.3 通期予想<br>(Forecast) |           |         |         |
|------------------------------------|-----------------|-------------|---------|-------|-----------|---------|-------|-----------|---------|-------|-----------|---------|-------|---------------------------|-----------|---------|---------|
|                                    |                 | 2014.3 3Q   |         |       | 2015.3 3Q |         |       | 2016.3 3Q |         |       | 2017.3 3Q |         |       |                           | 2018.3 3Q |         |         |
|                                    |                 | Ratio (%)   | YOY (%) |       | Ratio (%) | YOY (%) |       | Ratio (%) | YOY (%) |       | Ratio (%) | YOY (%) |       |                           | Ratio (%) | YOY (%) |         |
| 機器 Instrument                      |                 | 38,350      | 29.5    | 118.6 | 47,715    | 30.6    | 124.4 | 64,595    | 34.8    | 135.4 | 58,709    | 32.5    | 90.9  | 58,172                    | 28.7      | 99.1    | 90,100  |
| 試薬 Reagent                         |                 | 63,927      | 49.2    | 133.3 | 76,686    | 49.2    | 120.0 | 94,376    | 50.8    | 123.1 | 96,074    | 53.1    | 101.8 | 114,819                   | 56.7      | 119.5   | 151,200 |
| 保守サービス Maintenance Service & Parts |                 | 13,043      | 10.1    | 130.9 | 15,882    | 10.2    | 121.8 | 21,511    | 11.6    | 135.4 | 20,116    | 11.1    | 93.5  | 22,832                    | 11.3      | 113.5   | 30,900  |
| その他 ※1 Others ※1                   |                 | 14,527      | 11.2    | 130.5 | 15,567    | 10.0    | 107.2 | 5,201     | 2.8     | 33.4  | ※2 5,893  | 3.3     | 113.3 | 6,727                     | 3.3       | 114.2   | 7,800   |
| 合計 Total Sales                     |                 | 129,849     | 100.0   | 128.1 | 155,852   | 100.0   | 120.0 | 185,685   | 100.0   | 119.1 | 180,793   | 100.0   | 97.4  | 202,551                   | 100.0     | 112.0   | 280,000 |

※1 検査回数に応じて顧客に課金する取引について「その他」に含めておりましたが、2016年3月期以降「機器」「試薬」「保守サービス」に分割して表示しております。

※1 Transactions involving customer billings according to the number of times tests were performed were previously included in "Other Business." However, from the fiscal year ended March 31, 2016, these amounts are divided and presented in "Instrument," "Reagent" and "Maintenance Service &amp; Parts."

※2 中国地域において、2016年3月期までは消耗品を「試薬」に計上していましたが、2017年3月期より「その他」に組み替えております。

※2 In China region, sales of disposals have been adjusted in "Others" from the fiscal year ended in March 31, 2017 which was formally included in "Reagents".

● 通期予想は、2017年11月に修正したものです。

● Business forecast was revised in November 2017.

地域別・事業別売上高  
Net Sales by Destination and Business

■ 国内 Japan

(百万円)  
(¥ million)

| 事業 Business                  | 決算期 Fiscal Term | 日本基準 J-GAAP |           |         |           |           |         | IFRS      |           |         |           |           |         |           |           |         |
|------------------------------|-----------------|-------------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|
|                              |                 | 2014.3 3Q   |           |         | 2015.3 3Q |           |         | 2016.3 3Q |           |         | 2017.3 3Q |           |         | 2018.3 3Q |           |         |
|                              |                 |             | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |
| 血球計数検査 Hematology            |                 | 12,020      | 43.1      | 96.9    | 12,191    | 42.9      | 101.4   | 12,580    | 44.2      | 103.2   | 13,354    | 43.3      | 106.2   | 13,327    | 41.3      | 99.8    |
| 尿検査 Urinalysis               |                 | 1,557       | 5.6       | 109.3   | 1,490     | 5.2       | 95.7    | 1,623     | 5.7       | 108.9   | 1,739     | 5.6       | 107.1   | 1,799     | 5.6       | 103.5   |
| HU事業 HU Business             |                 | 13,577      | 48.7      | 98.2    | 13,681    | 48.2      | 100.8   | 14,203    | 49.9      | 103.8   | 15,094    | 48.9      | 106.3   | 15,127    | 46.9      | 100.2   |
| 免疫検査 Immunochemistry         |                 | 1,564       | 5.6       | 111.0   | 1,927     | 6.8       | 123.2   | 2,495     | 8.8       | 129.5   | 3,122     | 10.1      | 125.1   | 3,397     | 10.5      | 108.8   |
| 生化学検査 Clinical Chemistry     |                 | 1,491       | 5.3       | 113.2   | 1,161     | 4.1       | 77.9    | 1,054     | 3.7       | 90.8    | 1,110     | 3.6       | 105.3   | 1,162     | 3.6       | 104.7   |
| 血液凝固検査 Hemostasis            |                 | 4,593       | 16.5      | 102.8   | 4,672     | 16.5      | 101.7   | 5,105     | 17.9      | 109.3   | 5,356     | 17.4      | 104.9   | 5,671     | 17.6      | 105.9   |
| ICH事業 ICH Business           |                 | 7,648       | 27.4      | 106.3   | 7,761     | 27.3      | 101.5   | 8,655     | 30.4      | 111.5   | 9,589     | 31.1      | 110.8   | 10,231    | 31.7      | 106.7   |
| コア事業 Core-Business           |                 | 21,226      | 76.1      | 101.0   | 21,443    | 75.5      | 101.0   | 22,859    | 80.4      | 106.6   | 24,683    | 80.0      | 108.0   | 25,359    | 78.6      | 102.7   |
| FCM事業 FCM Business           |                 | -           | -         | -       | -         | -         | -       | 13        | 0.0       | -       | 44        | 0.1       | 340.7   | 28        | 0.1       | 63.6    |
| LS事業 Life Science Business   |                 | 166         | 0.6       | 98.8    | 166       | 0.6       | 100.2   | 157       | 0.6       | 94.5    | 705       | 2.3       | 447.8   | 1,134     | 3.5       | 160.9   |
| その他 Other Next-Core Business |                 | -           | -         | -       | -         | -         | -       | -         | -         | -       | -         | -         | -       | 0         | 0.0       | -       |
| ネクストコア事業 Next-Core Business  |                 | 166         | 0.6       | 98.8    | 166       | 0.6       | 100.2   | 170       | 0.6       | 102.3   | 750       | 2.4       | 439.6   | 1,162     | 3.6       | 154.9   |
| その他 ※ Other Business ※       |                 | 6,503       | 23.3      | 104.0   | 6,778     | 23.9      | 104.2   | 5,413     | 19.0      | 79.9    | 5,436     | 17.6      | 100.4   | 5,728     | 17.8      | 105.4   |
| 合計 Total Sales               |                 | 27,896      | 100.0     | 101.7   | 28,389    | 100.0     | 101.8   | 28,444    | 100.0     | 100.2   | 30,870    | 100.0     | 108.5   | 32,251    | 100.0     | 104.5   |

■ 海外 Overseas

| 事業 Business                  | 決算期 Fiscal Term | 日本基準 J-GAAP |           |         |           |           |         | IFRS      |           |         |           |           |         |           |           |         |
|------------------------------|-----------------|-------------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|
|                              |                 | 2014.3 3Q   |           |         | 2015.3 3Q |           |         | 2016.3 3Q |           |         | 2017.3 3Q |           |         | 2018.3 3Q |           |         |
|                              |                 |             | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |
| 血球計数検査 Hematology            |                 | 73,026      | 71.6      | 136.3   | 88,345    | 69.3      | 121.0   | 106,953   | 68.0      | 121.1   | 100,946   | 67.3      | 94.4    | 113,262   | 66.5      | 112.2   |
| 尿検査 Urinalysis               |                 | 8,801       | 8.6       | 134.4   | 10,331    | 8.1       | 117.4   | 11,999    | 7.6       | 116.2   | 10,007    | 6.7       | 83.4    | 13,374    | 7.9       | 133.6   |
| HU事業 HU Business             |                 | 81,827      | 80.3      | 136.1   | 98,676    | 77.4      | 120.6   | 118,953   | 75.7      | 120.5   | 110,954   | 74.0      | 93.3    | 126,636   | 74.4      | 114.1   |
| 免疫検査 Immunochemistry         |                 | 17          | 0.0       | 105.6   | 370       | 0.3       | 2,100.7 | 1,599     | 1.0       | 432.2   | 2,746     | 1.8       | 171.8   | 4,512     | 2.6       | 164.3   |
| 生化学検査 Clinical Chemistry     |                 | 1,014       | 1.0       | 161.2   | 1,612     | 1.3       | 158.9   | 1,644     | 1.0       | 102.0   | 1,435     | 1.0       | 87.3    | 1,413     | 0.8       | 98.5    |
| 血液凝固検査 Hemostasis            |                 | 14,975      | 14.7      | 147.3   | 18,591    | 14.6      | 124.1   | 26,235    | 16.7      | 141.1   | 25,865    | 17.3      | 98.6    | 25,958    | 15.2      | 100.4   |
| ICH事業 ICH Business           |                 | 16,007      | 15.7      | 148.1   | 20,573    | 16.1      | 128.5   | 29,479    | 18.7      | 143.3   | 30,048    | 20.0      | 101.9   | 31,884    | 18.7      | 106.1   |
| コア事業 Core-Business           |                 | 97,835      | 96.0      | 138.0   | 119,249   | 93.6      | 121.9   | 148,433   | 94.4      | 124.5   | 141,002   | 94.0      | 95.0    | 158,520   | 93.1      | 112.4   |
| FCM事業 FCM Business           |                 | -           | -         | -       | 1,905     | 1.5       | -       | 1,783     | 1.1       | 93.6    | 1,225     | 0.8       | 68.7    | 1,126     | 0.7       | 91.9    |
| LS事業 Life Science Business   |                 | 912         | 0.9       | 163.9   | 1,941     | 1.5       | 212.8   | 2,398     | 1.5       | 123.5   | 2,453     | 1.6       | 102.3   | 4,882     | 2.9       | 199.0   |
| その他 Other Next-Core Business |                 | -           | -         | -       | -         | -         | -       | -         | -         | -       | -         | -         | -       | -         | -         | -       |
| ネクストコア事業 Next-Core Business  |                 | 912         | 0.9       | 163.9   | 3,847     | 3.0       | 421.7   | 4,181     | 2.7       | 108.7   | 3,678     | 2.5       | 88.0    | 6,008     | 3.5       | 163.3   |
| その他 ※ Other Business ※       |                 | 3,205       | 3.1       | 130.1   | 4,366     | 3.4       | 136.2   | 4,626     | 2.9       | 105.9   | 5,241     | 3.5       | 113.3   | 5,770     | 3.4       | 110.1   |
| 合計 Total Sales               |                 | 101,953     | 100.0     | 137.9   | 127,463   | 100.0     | 125.0   | 157,241   | 100.0     | 123.4   | 149,923   | 100.0     | 95.3    | 170,300   | 100.0     | 113.6   |

※ 臨床検査情報システム、仕入れ商品等  
※ Clinical laboratory information systems, sales of third-party products, others

■ 米州 Americas

(百万円)  
(\$ million)

| 事業 Business                 | 決算期 Fiscal Term | 日本基準 J-GAAP |           |         |           |           |         | IFRS      |           |           |           |           |         |           |           |         |
|-----------------------------|-----------------|-------------|-----------|---------|-----------|-----------|---------|-----------|-----------|-----------|-----------|-----------|---------|-----------|-----------|---------|
|                             |                 | 2014.3 3Q   |           |         | 2015.3 3Q |           |         | 2016.3 3Q |           |           | 2017.3 3Q |           |         | 2018.3 3Q |           |         |
|                             |                 |             | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%)   |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |
| 血球計数検査 Hematology           |                 | 24,906      | 88.4      | 134.1   | 30,552    | 90.0      | 122.7   | 38,851    | 89.2      | 127.2     | 38,503    | 90.0      | 99.1    | 41,302    | 88.6      | 107.3   |
| 尿検査 Urinalysis              |                 | 1,575       | 5.6       | 115.4   | 1,351     | 4.0       | 85.8    | 1,899     | 4.4       | 140.5     | 1,385     | 3.2       | 73.0    | 1,930     | 4.1       | 139.4   |
| HU事業 HU Business            |                 | 26,481      | 94.0      | 132.8   | 31,903    | 94.0      | 120.5   | 40,750    | 93.5      | 127.7     | 39,889    | 93.2      | 97.9    | 43,233    | 92.8      | 108.4   |
| 免疫検査 Immunochemistry        |                 | -           | -         | -       | -         | -         | -       | -         | -         | -         | 0         | 0.0       | -       | -         | -         | -       |
| 生化学検査 Clinical Chemistry    |                 | -           | -         | -       | -         | -         | -       | -         | -         | -         | -         | -         | -       | -         | -         | -       |
| 血液凝固検査 Hemostasis           |                 | 1,590       | 5.6       | 147.3   | 1,813     | 5.3       | 114.0   | 2,146     | 4.9       | 118.4     | 2,395     | 5.6       | 111.6   | 2,005     | 4.3       | 83.7    |
| ICH事業 ICH Business          |                 | 1,590       | 5.6       | 147.3   | 1,813     | 5.3       | 114.0   | 2,146     | 4.9       | 118.4     | 2,396     | 5.6       | 111.6   | 2,005     | 4.3       | 83.7    |
| コア事業 Core-Business          |                 | 28,071      | 99.7      | 133.6   | 33,717    | 99.4      | 120.1   | 42,897    | 98.4      | 127.2     | 42,285    | 98.8      | 98.6    | 45,238    | 97.1      | 107.0   |
| FCM事業 FCM Business          |                 | -           | -         | -       | 90        | 0.3       | -       | 137       | 0.3       | 151.3     | 154       | 0.4       | 112.1   | 156       | 0.3       | 101.3   |
| LS事業 Life Science Business  |                 | -           | -         | -       | 0         | 0.0       | -       | 453       | 1.0       | 304,062.7 | 269       | 0.6       | 59.6    | 1,137     | 2.4       | 422.7   |
| その他 Other Next-Core         |                 | -           | -         | -       | -         | -         | -       | -         | -         | -         | -         | -         | -       | -         | -         | -       |
| ネクストコア事業 Next-Core Business |                 | -           | -         | -       | 90        | 0.3       | -       | 590       | 1.4       | 649.1     | 424       | 1.0       | 71.8    | 1,294     | 2.8       | 305.2   |
| その他 ※ Other Business ※      |                 | 95          | 0.3       | 258.2   | 125       | 0.4       | 131.8   | 88        | 0.2       | 70.3      | 94        | 0.2       | 107.0   | 78        | 0.2       | 83.0    |
| 合計 Total Sales              |                 | 28,166      | 100.0     | 133.8   | 33,933    | 100.0     | 120.5   | 43,576    | 100.0     | 128.4     | 42,803    | 100.0     | 98.2    | 46,612    | 100.0     | 108.9   |

■ EMEA(欧州、中東、アフリカ地域 / Europe, the Middle East and Africa)

| 事業 Business                 | 決算期 Fiscal Term | 日本基準 J-GAAP |           |         |           |           |         | IFRS      |           |         |           |           |         |           |           |         |
|-----------------------------|-----------------|-------------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|
|                             |                 | 2014.3 3Q   |           |         | 2015.3 3Q |           |         | 2016.3 3Q |           |         | 2017.3 3Q |           |         | 2018.3 3Q |           |         |
|                             |                 |             | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |
| 血球計数検査 Hematology           |                 | 27,665      | 73.1      | 137.6   | 32,380    | 68.6      | 117.0   | 35,883    | 69.6      | 110.8   | 32,809    | 70.0      | 91.4    | 36,613    | 68.6      | 111.6   |
| 尿検査 Urinalysis              |                 | 2,266       | 6.0       | 135.9   | 2,507     | 5.3       | 110.6   | 2,523     | 4.9       | 100.6   | 2,131     | 4.5       | 84.5    | 2,737     | 5.1       | 128.4   |
| HU事業 HU Business            |                 | 29,931      | 79.1      | 137.5   | 34,887    | 73.9      | 116.6   | 38,406    | 74.5      | 110.1   | 34,941    | 74.6      | 91.0    | 39,351    | 73.7      | 112.6   |
| 免疫検査 Immunochemistry        |                 | 10          | 0.0       | 92.3    | 6         | 0.0       | 63.3    | 4         | 0.0       | 70.0    | 0         | 0.0       | 19.6    | 0         | 0.0       | 1.4     |
| 生化学検査 Clinical Chemistry    |                 | 162         | 0.4       | 146.7   | 232       | 0.5       | 143.0   | 177       | 0.3       | 76.4    | 7         | 0.0       | 4.0     | 18        | 0.0       | 257.1   |
| 血液凝固検査 Hemostasis           |                 | 4,256       | 11.2      | 128.7   | 4,925     | 10.4      | 115.7   | 5,636     | 10.9      | 114.5   | 4,579     | 9.8       | 81.2    | 4,652     | 8.7       | 101.6   |
| ICH事業 ICH Business          |                 | 4,430       | 11.7      | 129.2   | 5,164     | 10.9      | 116.6   | 5,819     | 11.3      | 112.7   | 4,587     | 9.8       | 78.8    | 4,671     | 8.8       | 101.8   |
| コア事業 Core-Business          |                 | 34,361      | 90.8      | 136.3   | 40,051    | 84.9      | 116.6   | 44,226    | 85.8      | 110.4   | 39,528    | 84.3      | 89.4    | 44,022    | 82.5      | 111.4   |
| FCM事業 FCM Business          |                 | -           | -         | -       | 1,802     | 3.8       | -       | 1,392     | 2.7       | 77.2    | 854       | 1.8       | 61.4    | 641       | 1.2       | 75.1    |
| LS事業 Life Science Business  |                 | 886         | 2.3       | 159.3   | 1,939     | 4.1       | 218.7   | 1,940     | 3.8       | 100.1   | 2,184     | 4.7       | 112.6   | 3,699     | 6.9       | 169.4   |
| その他 Other Next-Core         |                 | -           | -         | -       | -         | -         | -       | -         | -         | -       | -         | -         | -       | -         | -         | -       |
| ネクストコア事業 Next-Core Business |                 | 886         | 2.3       | 159.3   | 3,741     | 7.9       | 422.0   | 3,333     | 6.5       | 89.1    | 3,039     | 6.5       | 91.2    | 4,341     | 8.1       | 142.8   |
| その他 ※ Other Business ※      |                 | 2,614       | 6.9       | 131.9   | 3,400     | 7.2       | 130.1   | 4,014     | 7.8       | 118.1   | 4,295     | 9.2       | 107.0   | 4,996     | 9.4       | 116.3   |
| 合計 Total Sales              |                 | 37,862      | 100.0     | 136.5   | 47,194    | 100.0     | 124.6   | 51,573    | 100.0     | 109.3   | 46,863    | 100.0     | 90.9    | 53,360    | 100.0     | 113.9   |

※ 臨床検査情報システム、仕入れ商品等

※ Clinical laboratory information systems, sales of third-party products, others

■ 中国 China

(百万円)  
(¥ million)

| 決算期 Fiscal Term             | 日本基準 J-GAAP |           |         |           |           |         | IFRS      |           |         |           |           |         |           |           |         |
|-----------------------------|-------------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|
|                             | 2014.3 3Q   |           |         | 2015.3 3Q |           |         | 2016.3 3Q |           |         | 2017.3 3Q |           |         | 2018.3 3Q |           |         |
|                             |             | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |
| 事業 Business                 |             |           |         |           |           |         |           |           |         |           |           |         |           |           |         |
| 血球計数検査 Hematology           | 13,506      | 51.8      | 139.1   | 17,591    | 50.8      | 130.2   | 23,055    | 47.5      | 131.1   | 19,702    | 43.4      | 85.5    | 23,275    | 44.5      | 118.1   |
| 尿検査 Urinalysis              | 4,158       | 16.0      | 134.6   | 5,438     | 15.7      | 130.8   | 6,384     | 13.2      | 117.4   | 5,425     | 11.9      | 85.0    | 7,188     | 13.7      | 132.5   |
| HU事業 HU Business            | 17,664      | 67.8      | 138.0   | 23,030    | 66.5      | 130.4   | 29,439    | 60.7      | 127.8   | 25,127    | 55.3      | 85.4    | 30,463    | 58.2      | 121.2   |
| 免疫検査 Immunochemistry        | 4           | 0.0       | 110.3   | 345       | 1.0       | 8,342.5 | 1,567     | 3.2       | 453.5   | 2,577     | 5.7       | 164.4   | 4,278     | 8.2       | 166.0   |
| 生化学検査 Clinical Chemistry    | 748         | 2.9       | 162.5   | 1,059     | 3.1       | 141.6   | 933       | 1.9       | 88.1    | 875       | 1.9       | 93.8    | 742       | 1.4       | 84.8    |
| 血液凝固検査 Hemostasis           | 7,537       | 28.9      | 164.8   | 10,198    | 29.4      | 135.3   | 16,549    | 34.1      | 162.3   | 16,772    | 36.9      | 101.4   | 16,734    | 32.0      | 99.8    |
| ICH事業 ICH Business          | 8,290       | 31.8      | 164.5   | 11,604    | 33.5      | 140.0   | 19,050    | 39.3      | 164.2   | 20,225    | 44.5      | 106.2   | 21,754    | 41.6      | 107.6   |
| コア事業 Core-Business          | 25,955      | 99.6      | 145.5   | 34,634    | 100.0     | 133.4   | 48,490    | 99.9      | 140.0   | 45,353    | 99.8      | 93.5    | 52,218    | 99.8      | 115.1   |
| FCM事業 FCM Business          | -           | -         | -       | -         | -         | -       | 26        | 0.1       | -       | 91        | 0.2       | 347.7   | 79        | 0.2       | 86.8    |
| LS事業 Life Science Business  | -           | -         | -       | -         | -         | -       | -         | -         | -       | -         | -         | -       | 21        | 0.0       | -       |
| その他 Other Next-Core         | -           | -         | -       | -         | -         | -       | -         | -         | -       | -         | -         | -       | -         | -         | -       |
| ネクストコア事業 Next-Core Business | -           | -         | -       | -         | -         | -       | 26        | 0.1       | -       | 91        | 0.2       | 347.7   | 101       | 0.2       | 111.0   |
| その他 ※ Other Business ※      | 108         | 0.4       | 69.5    | 2         | 0.0       | 2.2     | 0         | 0.0       | 17.6    | -         | -         | -       | 1         | 0.0       | -       |
| 合計 Total Sales              | 26,063      | 100.0     | 144.9   | 34,636    | 100.0     | 132.9   | 48,517    | 100.0     | 140.1   | 45,444    | 100.0     | 93.7    | 52,321    | 100.0     | 115.1   |

■ アジア・パシフィック Asia-Pacific

| 決算期 Fiscal Term             | 日本基準 J-GAAP |           |         |           |           |         | IFRS      |           |         |           |           |         |           |           |         |
|-----------------------------|-------------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|
|                             | 2014.3 3Q   |           |         | 2015.3 3Q |           |         | 2016.3 3Q |           |         | 2017.3 3Q |           |         | 2018.3 3Q |           |         |
|                             |             | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |
| 事業 Business                 |             |           |         |           |           |         |           |           |         |           |           |         |           |           |         |
| 血球計数検査 Hematology           | 6,948       | 70.5      | 134.3   | 7,820     | 66.9      | 112.6   | 9,163     | 67.5      | 117.2   | 9,931     | 67.0      | 108.4   | 12,070    | 67.0      | 121.5   |
| 尿検査 Urinalysis              | 801         | 8.1       | 187.3   | 1,033     | 8.8       | 129.0   | 1,192     | 8.8       | 115.4   | 1,065     | 7.2       | 89.3    | 1,517     | 8.4       | 142.4   |
| HU事業 HU Business            | 7,749       | 78.6      | 138.3   | 8,854     | 75.7      | 114.3   | 10,356    | 76.3      | 117.0   | 10,996    | 74.2      | 106.2   | 13,587    | 75.5      | 123.6   |
| 免疫検査 Immunochemistry        | 2           | 0.0       | 200.3   | 17        | 0.2       | 614.6   | 26        | 0.2       | 151.7   | 167       | 1.1       | 629.4   | 234       | 1.3       | 140.1   |
| 生化学検査 Clinical Chemistry    | 103         | 1.0       | 178.0   | 319       | 2.7       | 309.3   | 533       | 3.9       | 166.9   | 553       | 3.7       | 103.7   | 652       | 3.6       | 117.9   |
| 血液凝固検査 Hemostasis           | 1,590       | 16.1      | 132.2   | 1,654     | 14.1      | 104.0   | 1,903     | 14.0      | 115.0   | 2,117     | 14.3      | 111.3   | 2,565     | 14.3      | 121.2   |
| ICH事業 ICH Business          | 1,696       | 17.2      | 134.4   | 1,991     | 17.0      | 117.4   | 2,463     | 18.1      | 123.7   | 2,838     | 19.2      | 115.2   | 3,452     | 19.2      | 121.6   |
| コア事業 Core-Business          | 9,446       | 95.8      | 137.6   | 10,846    | 92.7      | 114.8   | 12,819    | 94.4      | 118.2   | 13,834    | 93.4      | 107.9   | 17,040    | 94.6      | 123.2   |
| FCM事業 FCM Business          | -           | -         | -       | 11        | 0.1       | -       | 227       | 1.7       | 1,904.4 | 125       | 0.9       | 55.4    | 249       | 1.4       | 199.2   |
| LS事業 Life Science Business  | 25          | 0.3       | -       | 2         | 0.0       | 8.9     | 4         | 0.0       | 189.7   | △ 1       | △ 0.0     | △ 38.4  | 22        | 0.1       | -       |
| その他 Other Next-Core         | -           | -         | -       | -         | -         | -       | -         | -         | -       | -         | -         | -       | -         | -         | -       |
| ネクストコア事業 Next-Core Business | 25          | 0.3       | -       | 14        | 0.1       | 55.5    | 231       | 1.7       | 1,630.9 | 124       | 0.8       | 53.7    | 271       | 1.5       | 218.5   |
| その他 ※ Other Business ※      | 387         | 3.9       | 134.4   | 838       | 7.2       | 216.4   | 522       | 3.9       | 62.4    | 852       | 5.8       | 163.0   | 693       | 3.9       | 81.3    |
| 合計 Total Sales              | 9,859       | 100.0     | 137.8   | 11,698    | 100.0     | 118.7   | 13,573    | 100.0     | 116.0   | 14,811    | 100.0     | 109.1   | 18,005    | 100.0     | 121.6   |

※ 臨床検査情報システム、仕入れ商品等

※ Clinical laboratory information systems, sales of third-party products, others

地域別・品目別売上高  
Net Sales by Destination and Product type

(百万円)  
(¥ million)

| 地域 Destination<br>品目 Product Type ※1 |                                    |         | 日本基準 J-GAAP |         |         |           |         |         | IFRS      |         |          |           |         |         |           |         |  |
|--------------------------------------|------------------------------------|---------|-------------|---------|---------|-----------|---------|---------|-----------|---------|----------|-----------|---------|---------|-----------|---------|--|
|                                      |                                    |         | 2014.3 3Q   |         |         | 2015.3 3Q |         |         | 2016.3 3Q |         |          | 2017.3 3Q |         |         | 2018.3 3Q |         |  |
|                                      |                                    |         | Ratio (%)   | YOY (%) |         | Ratio (%) | YOY (%) |         | Ratio (%) | YOY (%) |          | Ratio (%) | YOY (%) |         | Ratio (%) | YOY (%) |  |
| 日本<br>Japan                          | 機器 Instrument                      | 7,936   | 28.5        | 99.9    | 7,572   | 26.7      | 95.4    | 6,000   | 21.1      | 79.2    | 6,230    | 20.2      | 103.8   | 6,223   | 19.3      | 99.9    |  |
|                                      | 試薬 Reagent                         | 15,295  | 54.8        | 101.2   | 16,179  | 57.0      | 105.8   | 17,518  | 61.6      | 108.3   | 18,989   | 61.5      | 108.4   | 20,339  | 63.1      | 107.1   |  |
|                                      | 保守サービス Maintenance Service & Parts | 2,865   | 10.3        | 108.8   | 3,032   | 10.7      | 105.8   | 3,256   | 11.4      | 107.4   | 3,913    | 12.7      | 120.2   | 4,052   | 12.6      | 103.6   |  |
|                                      | その他 Others                         | 1,798   | 6.4         | 102.4   | 1,605   | 5.6       | 89.3    | 1,668   | 5.9       | 103.9   | 1,736    | 5.6       | 104.1   | 1,635   | 5.1       | 94.2    |  |
|                                      | 合計 Total Sales                     | 27,896  | 100.0       | 101.7   | 28,389  | 100.0     | 101.8   | 28,444  | 100.0     | 100.2   | 30,870   | 100.0     | 108.5   | 32,251  | 100.0     | 104.5   |  |
| 米州<br>Americas                       | 機器 Instrument                      | 7,314   | 26.0        | 127.5   | 9,602   | 28.3      | 131.3   | 15,013  | 34.5      | 156.4   | 15,425   | 36.0      | 102.7   | 14,891  | 31.9      | 96.5    |  |
|                                      | 試薬 Reagent                         | 10,138  | 36.0        | 136.3   | 12,007  | 35.4      | 118.4   | 17,137  | 39.3      | 142.7   | 16,920   | 39.5      | 98.7    | 19,795  | 42.5      | 117.0   |  |
|                                      | 保守サービス Maintenance Service & Parts | 6,148   | 21.8        | 139.3   | 7,303   | 21.5      | 118.8   | 11,061  | 25.4      | 151.4   | 10,033   | 23.4      | 90.7    | 11,439  | 24.5      | 114.0   |  |
|                                      | その他 Others                         | 4,566   | 16.2        | 131.9   | 5,020   | 14.8      | 109.9   | 363     | 0.8       | 7.3     | 423      | 1.0       | 116.5   | 486     | 1.0       | 114.9   |  |
|                                      | 合計 Total Sales                     | 28,166  | 100.0       | 133.8   | 33,933  | 100.0     | 120.5   | 43,576  | 100.0     | 128.4   | 42,803   | 100.0     | 98.2    | 46,612  | 100.0     | 108.9   |  |
| EMEA                                 | 機器 Instrument                      | 9,229   | 24.4        | 125.2   | 12,540  | 26.6      | 135.9   | 16,368  | 31.7      | 130.5   | 14,590   | 31.1      | 89.1    | 15,132  | 28.4      | 103.7   |  |
|                                      | 試薬 Reagent                         | 18,601  | 49.1        | 143.2   | 22,724  | 48.1      | 122.2   | 26,296  | 51.0      | 115.7   | 25,128   | 53.6      | 95.6    | 29,767  | 55.8      | 118.5   |  |
|                                      | 保守サービス Maintenance Service & Parts | 3,474   | 9.2         | 139.1   | 4,820   | 10.2      | 138.7   | 6,169   | 12.0      | 128.0   | 5,017    | 10.7      | 81.3    | 5,963   | 11.2      | 118.9   |  |
|                                      | その他 Others                         | 6,557   | 17.3        | 134.3   | 7,108   | 15.1      | 108.4   | 2,738   | 5.3       | 38.5    | 2,126    | 4.5       | 77.6    | 2,497   | 4.7       | 117.5   |  |
|                                      | 合計 Total Sales                     | 37,862  | 100.0       | 136.5   | 47,194  | 100.0     | 124.6   | 51,573  | 100.0     | 109.3   | 46,863   | 100.0     | 90.9    | 53,360  | 100.0     | 113.9   |  |
| 中国<br>China                          | 機器 Instrument                      | 11,501  | 44.1        | 127.5   | 15,174  | 43.8      | 131.9   | 23,454  | 48.3      | 154.6   | 17,581   | 38.7      | 75.0    | 16,319  | 31.2      | 92.8    |  |
|                                      | 試薬 Reagent                         | 14,326  | 55.0        | 162.8   | 19,186  | 55.4      | 133.9   | 24,729  | 51.0      | 128.9   | 26,375   | 58.0      | 106.7   | 34,091  | 65.2      | 129.3   |  |
|                                      | 保守サービス Maintenance Service & Parts | 207     | 0.8         | 139.7   | 239     | 0.7       | 115.4   | 309     | 0.6       | 129.2   | 283      | 0.6       | 91.6    | 406     | 0.8       | 143.5   |  |
|                                      | その他 Others                         | 28      | 0.1         | 117.8   | 36      | 0.1       | 130.1   | 23      | 0.1       | 65.2    | ※2 1,204 | 2.7       | 5,234.8 | 1,504   | 2.9       | 124.9   |  |
|                                      | 合計 Total Sales                     | 26,063  | 100.0       | 144.9   | 34,636  | 100.0     | 132.9   | 48,517  | 100.0     | 140.1   | 45,444   | 100.0     | 93.7    | 52,321  | 100.0     | 115.1   |  |
| アジア・<br>パシフィック<br>Asia-<br>Pacific   | 機器 Instrument                      | 2,368   | 24.0        | 104.5   | 2,827   | 24.2      | 119.4   | 3,758   | 27.7      | 133.0   | 4,880    | 33.0      | 129.9   | 5,605   | 31.1      | 114.9   |  |
|                                      | 試薬 Reagent                         | 5,565   | 56.5        | 154.1   | 6,587   | 56.3      | 118.4   | 8,694   | 64.0      | 132.0   | 8,660    | 58.5      | 99.6    | 10,826  | 60.1      | 125.0   |  |
|                                      | 保守サービス Maintenance Service & Parts | 348     | 3.5         | 127.9   | 486     | 4.1       | 139.6   | 714     | 5.3       | 146.9   | 868      | 5.9       | 121.6   | 970     | 5.4       | 111.8   |  |
|                                      | その他 Others                         | 1,577   | 16.0        | 157.3   | 1,797   | 15.4      | 113.9   | 405     | 3.0       | 22.6    | 402      | 2.7       | 99.3    | 603     | 3.4       | 150.0   |  |
|                                      | 合計 Total Sales                     | 9,859   | 100.0       | 137.8   | 11,698  | 100.0     | 118.7   | 13,573  | 100.0     | 116.0   | 14,811   | 100.0     | 109.1   | 18,005  | 100.0     | 121.6   |  |
| 計<br>Total                           | 機器 Instrument                      | 38,350  | 29.5        | 118.6   | 47,715  | 30.6      | 124.4   | 64,595  | 34.8      | 135.4   | 58,709   | 32.5      | 90.9    | 58,172  | 28.7      | 99.1    |  |
|                                      | 試薬 Reagent                         | 63,927  | 49.2        | 133.3   | 76,686  | 49.2      | 120.0   | 94,376  | 50.8      | 123.1   | 96,074   | 53.1      | 101.8   | 114,819 | 56.7      | 119.5   |  |
|                                      | 保守サービス Maintenance Service & Parts | 13,043  | 10.1        | 130.9   | 15,882  | 10.2      | 121.8   | 21,511  | 11.6      | 135.4   | 20,116   | 11.1      | 93.5    | 22,832  | 11.3      | 113.5   |  |
|                                      | その他 Others                         | 14,527  | 11.2        | 130.5   | 15,567  | 10.0      | 107.2   | 5,201   | 2.8       | 33.4    | ※2 5,893 | 3.3       | 113.3   | 6,727   | 3.3       | 114.2   |  |
|                                      | 合計 Total Sales                     | 129,849 | 100.0       | 128.1   | 155,852 | 100.0     | 120.0   | 185,685 | 100.0     | 119.1   | 180,793  | 100.0     | 97.4    | 202,551 | 100.0     | 112.0   |  |

※1 検査回数に応じて顧客に課金する取引について「その他」に含めておりましたが、2016年3月期以降「機器」「試薬」「保守サービス」に分割して表示しております。

※1 Transactions involving customer billings according to the number of times tests were performed were previously included in "Other Businesses." However, from the fiscal year ended March 31, 2016, these amounts are divided and presented in "Instrument," "Reagent" and "Maintenance Service & Parts."

※2 中国地域において、2016年3月期までは消耗品を「試薬」に計上していましたが、2017年3月期より「その他」に組み替えております。

※2 In China region, sales of disposals have been adjusted in "Others" from the fiscal year ended in March 31, 2017 which was formally included in "Reagents".

● EMEA: 欧州、中東、アフリカ地域

● EMEA: Europe, the Middle East and Africa

所在地別売上高および営業利益の状況 [第3四半期累計]

Net Sales and Operating Income (Loss) by Geographical Region

(Net Sales and Operating Income (Loss) of Subsidiaries in the Region) [3rd Quarter]

| 所在地 Geographical Region                 |       |                     | 2016.3 3Q |           |         | 2017.3 3Q |           |         | 2018.3 3Q |           |         | 2018.3 通期予想<br>Forecast |
|---|-------|---------------------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|-------------------------|
|   |       |                     |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |           | Ratio (%) | YOY (%) |                         |
| 日本<br>Japan                             | 外部売上高 | Sales to Customers  | 30,993    | 30.3      | -       | 32,732    | 31.7      | 105.6   | 33,643    | 31.7      | 102.8   | 47,500                  |
|   | 内部売上高 | Intra-area Transfer | 71,209    | 69.7      | -       | 70,389    | 68.3      | 98.8    | 72,654    | 68.3      | 103.2   | 104,200                 |
|   | 売上高計  | Total Sales         | 102,203   | 100.0     | -       | 103,121   | 100.0     | 100.9   | 106,297   | 100.0     | 103.1   | 151,700                 |
|   | 営業利益  | Operating Income    | 33,597    | 32.9      | -       | 27,225    | 26.4      | 81.0    | 29,825    | 28.1      | 109.6   | 38,400                  |
| 米州<br>Americas                          | 外部売上高 | Sales to Customers  | 40,941    | 98.3      | -       | 40,668    | 99.4      | 99.3    | 44,199    | 99.4      | 108.7   | 63,500                  |
|   | 内部売上高 | Intra-area Transfer | 690       | 1.7       | -       | 253       | 0.6       | 36.7    | 276       | 0.6       | 109.1   | 300                     |
|   | 売上高計  | Total Sales         | 41,631    | 100.0     | -       | 40,921    | 100.0     | 98.3    | 44,475    | 100.0     | 108.7   | 63,800                  |
|   | 営業利益  | Operating Income    | 1,537     | 3.7       | -       | 2,485     | 6.1       | 161.7   | 3,805     | 8.6       | 153.1   | 5,700                   |
| EMEA                                    | 外部売上高 | Sales to Customers  | 51,723    | 98.0      | -       | 47,208    | 95.9      | 91.3    | 54,528    | 96.7      | 115.5   | 73,300                  |
|   | 内部売上高 | Intra-area Transfer | 1,064     | 2.0       | -       | 2,041     | 4.1       | 191.8   | 1,836     | 3.3       | 90.0    | 2,200                   |
|   | 売上高計  | Total Sales         | 52,788    | 100.0     | -       | 49,250    | 100.0     | 93.3    | 56,365    | 100.0     | 114.4   | 75,500                  |
|   | 営業利益  | Operating Income    | 3,271     | 6.2       | -       | 3,694     | 7.5       | 112.9   | 4,351     | 7.7       | 117.8   | 6,400                   |
| 中国<br>China                             | 外部売上高 | Sales to Customers  | 48,477    | 100.0     | -       | 45,432    | 100.0     | 93.7    | 52,272    | 100.0     | 115.1   | 70,700                  |
|   | 内部売上高 | Intra-area Transfer | 3         | 0.0       | -       | 4         | 0.0       | 133.3   | 14        | 0.0       | 350.0   | -                       |
|   | 売上高計  | Total Sales         | 48,481    | 100.0     | -       | 45,436    | 100.0     | 93.7    | 52,286    | 100.0     | 115.1   | 70,700                  |
|   | 営業利益  | Operating Income    | 5,243     | 10.8      | -       | 2,579     | 5.7       | 49.2    | 6,062     | 11.6      | 235.1   | 6,400                   |
| アジア・パシフィック<br>Asia-Pacific              | 外部売上高 | Sales to Customers  | 13,548    | 99.9      | -       | 14,752    | 100.0     | 108.9   | 17,907    | 100.0     | 121.4   | 25,000                  |
|   | 内部売上高 | Intra-area Transfer | 19        | 0.1       | -       | 3         | -         | 15.8    | 3         | -         | 100.0   | -                       |
|   | 売上高計  | Total Sales         | 13,567    | 100.0     | -       | 14,755    | 100.0     | 108.8   | 17,911    | 100.0     | 121.4   | 25,000                  |
|   | 営業利益  | Operating Income    | 1,769     | 13.0      | -       | 1,596     | 10.8      | 90.2    | 2,207     | 12.3      | 138.3   | 2,500                   |
| 計<br>Total                              | 外部売上高 | Sales to Customers  | 185,685   | 71.8      | -       | 180,793   | 71.3      | 97.4    | 202,551   | 73.0      | 112.0   | 280,000                 |
|   | 内部売上高 | Intra-area Transfer | 72,987    | 28.2      | -       | 72,692    | 28.7      | 99.6    | 74,785    | 27.0      | 102.9   | 106,700                 |
|   | 売上高計  | Total Sales         | 258,672   | 100.0     | -       | 253,486   | 100.0     | 98.0    | 277,336   | 100.0     | 109.4   | 386,700                 |
|   | 営業利益  | Operating Income    | 45,419    | 17.6      | -       | 37,582    | 14.8      | 82.7    | 46,252    | 16.7      | 123.1   | 59,400                  |
| 消去/<br>全社<br>Eliminations/<br>Corporate | 外部売上高 | Sales to Customers  | -         | -         | -       | -         | -         | -       | -         | -         | -       | -                       |
|   | 内部売上高 | Intra-area Transfer | △72,987   | -         | -       | △72,692   | -         | -       | △74,785   | -         | -       | △106,700                |
|   | 売上高計  | Total Sales         | △72,987   | -         | -       | △72,692   | -         | -       | △74,785   | -         | -       | △106,700                |
|   | 営業利益  | Operating Income    | 612       | -         | -       | 1,578     | -         | -       | △1,668    | -         | -       | △1,400                  |
| 連結<br>Consolidated                      | 外部売上高 | Sales to Customers  | 185,685   | 100.0     | -       | 180,793   | 100.0     | 97.4    | 202,551   | 100.0     | 112.0   | 280,000                 |
|   | 内部売上高 | Intra-area Transfer | -         | -         | -       | -         | -         | -       | -         | -         | -       | -                       |
|   | 売上高計  | Total Sales         | 185,685   | 100.0     | -       | 180,793   | 100.0     | 97.4    | 202,551   | 100.0     | 112.0   | 280,000                 |
|   | 営業利益  | Operating Income    | 46,032    | 24.8      | -       | 39,160    | 21.7      | 85.1    | 44,583    | 22.0      | 113.8   | 58,000                  |

※1 日本所在地には、モンゴル、アイデックス社向けなどの売上、利益を含みます。

※1 Sales and Operating Income in Japan include those to Mongolia, IDEXX and other countries.

※2 アジア・パシフィック所在地には、モンゴルの売上、利益を含みません。

※2 Sales in Asia Pacific exclude Mongolia.

● EMEA: 欧州、中東、アフリカ地域

● EMEA: Europe, the Middle East and Africa



● 通期予想は、2017年11月に修正したものです。

● Business forecast was revised in November 2017.

株式情報

Stock Information


シスメックス株式会社の株価推移と出来高  
Stock Price Range and Trading Volume of Sysmex Corporation




※1: 2011年4月1日付で1株を2株に株式分割を実施しました。  
※1: The shares of shareholders was split two for one on April 1, 2011.

※2: 2014年4月1日付で1株を2株に株式分割を行っております。  
※2: The Company conducted a two-for-one stock split on April 1, 2014.


株式の所有者別状況  
Composition of Shareholders by Category



株主数の推移  
Number of Shareholders



発行済株式数の推移  
Number of Shares Issued (千株)  
(thousand shares)





## 会社概要

### Corporate Data

#### シスメックス株式会社

Sysmex Corporation

本社所在地  
Address of Head Office 〒651-0073 兵庫県神戸市中央区脇浜海岸通1丁目5番1号  
1-5-1, Wakinojima-Kaigandori, Chuo-ku, Kobe, Hyogo 651-0073, Japan

電話番号 Telephone (078) 265-0500 (代表)  
F A X Facsimile (078) 265-0524

設立年月日  
Date of Establishment 昭和43年2月20日  
February 20, 1968

資本金  
Paid-in Capital 12,013,900 (千円)  
(¥ thousand)

従業員数  
Number of Employees 2,564名 (単独/Non-Consolidated)  
8,442名 (連結/Consolidated)  
※嘱託及びパートタイマーなどを含む  
※including part-time employee  
従業員平均年齢 average age 40.5 才  
従業員平均勤続年数 average years of employment 11.7 年

発行済株式総数  
Number of Shares Issued 208,832 千株 ※  
(thousand shares)

決算期  
Settlement Day 3月31日  
March 31

上場市場  
Stock Listings 東京証券取引所市場第一部  
Tokyo Stock Exchange, First Section

証券コードNo.  
Stock Exchange Code Number 6869

主な事業内容  
Main Line of Business 臨床検査機器、検査用試薬ならびに関連ソフトウェアなどの  
開発・製造・販売・輸出入  
Development, manufacture, sales, import and export of diagnostics testing  
instruments and reagents, and related software

主な販売先  
Customers 国立病院、一般病院、大学、研究所、その他医療機関  
National and public hospitals, general hospitals,  
and other medical institutions, universities, and research institutes


|                |   |  |   |
|----------------|---|--|---|
| 事業所<br>Offices | 本社<br>Head Office<br>テクノパーク<br>Technopark<br>ソリューションセンター<br>Solution Center<br>研究開発センター<br>R&D Center<br>アイスクエア<br>i-Square<br>加古川工場<br>Kakogawa Factory<br>タンパク質開発センター<br>Protein Development Center<br>東京支社<br>Tokyo Office | 仙台支店<br>Sendai Branch<br>北関東支店<br>Kita Kanto Branch<br>東京支店<br>Tokyo Branch<br>名古屋支店<br>Nagoya Branch<br>大阪支店<br>Osaka Branch<br>広島支店<br>Hiroshima Branch<br>福岡支店<br>Fukuoka Branch<br>札幌営業所<br>Sapporo Sales Office<br>盛岡営業所<br>Morioka Sales Office<br>長野営業所<br>Nagano Sales Office<br>新潟営業所<br>Niigata Sales Office | 千葉営業所<br>Chiba Sales Office<br>横浜営業所<br>Yokohama Sales Office<br>静岡営業所<br>Shizuoka Sales Office<br>金沢営業所<br>Kanazawa Sales Office<br>京都営業所<br>Kyoto Sales Office<br>神戸営業所<br>Kobe Sales Office<br>高松営業所<br>Takamatsu Sales Office<br>岡山営業所<br>Okayama Sales Office<br>鹿児島営業所<br>Kagoshima Sales Office<br>首都圏サービスセンター<br>Metropolitan Area Service Center |
|----------------|---|--|---|

※：2014年4月1日付で1株を2株に株式分割を行っております。  
そのため、前連結会計年度の期首に当該分割が行われたと仮定して期末発行済株式数を算定しております。

※：The Company conducted a two-for-one stock split on April 1, 2014.

Accordingly, calculations involving the number of shares issued as of the end of the fiscal year are performed as if the stock split had been conducted at the beginning of the previous fiscal year.

(2017年12月31日現在)  
(As of December 31, 2016)



**Sysmex Corporation**

1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan  
Tel. +81(78)265-0500 Fax. +81(78)265-0524

[www.sysmex.co.jp](http://www.sysmex.co.jp)

Printed in Japan